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FOETAL ANTIGENS - CURRENT
CLINICAL APPLICATIONS. A. MUNRO
NEVILLE. Division of Pathology, Chester
Beatty Research Institute, London.
For many years past, the energies of many
scientists have been devoted to attempting to
evolve a test, or series of tests, with universal
application to facilitating the diagnosis not
only of primary but also of metastatic
tumours. Many have been proposed; none
has yet proved satisfactory.
The recent evidence that human tumours
express distinct neoantigens has provided a
new approach to the problem. The onco-
foetal antigens represent one class of tumour
associated antigens which are released by the
tumours into the body fluids. Many have
now been described, of which the carcino-
embryonic antigen (CEA) and alpha-foeto-
protein (AFP) have been studied in greatest
detail.
Raised levels of plasma CEA or CEA-like
material occur with a wide variety of tumours
of different histogenesis. The mass of
tumours and their extent of spread are
important in determining the plasma levels.
Inflammatory conditions also raise their
levels. Hence, it would seem to have little
value in assisting with the earlier or differ-
ential diagnosis of malignancy. Recent
evidence tends to suggest that the prognosis
of a particular tumour may be related to the
pre-operative CEA levels. Moreover, rises in
plasma CEA may antedate by 3-18 months
the clinical detection of recurrent or metasta-
tic colorectal tumours.
CEA or CEA-like materials also occur in
biological fluids other than plasma and their
diagnostic role in such sites remains to be
examined with the exception of urine and
urothelial carcinoma.
Elevated plasma levels of AFP were
originally considered to be specific for
hepatocellular carcinoma and malignant tera-
tomata of gonadal and extra-gonadal origin.
With the development of sensitive radio-
immunoassays, other tumours including
gastrointestinal and prostatic carcinomata
and non-neoplastic hepatic disease, may yield
plasma levels which overlap with those found
in primary liver cancer. Moreover, raised
AFP levels have not been found in the pre-
clinical phase of this tumour.
Thus, like CEA, AFP seems to offer little
in the diagnostic phase. Its principal role
seems to be as an index of recurrent or
metastatic disease.
CLINICAL AND TECHNICAL EVALUA-
TION OF THE MOD-NEM TEST FOR
MALIGNANT DISEASE. J. A. V.
PRITCHARD, J. L. MOORE, W. H. SUTHER-
LAND and C. A. F. JOSLIN. Tenovus
Laboratories, Velindre Hospital, Whitchurch,
Cardiff.
Field and Caspary (Lancet, 1970, ii, 1337;
Br. med. J., 1971, ii, 613) reported that
peripheral lymphocytes from patients with
malignant disease were sensitized to a basic
protein (EF) derived from human brain.
Sensitized lymphocytes in contact with EF
produce a substance (macrophage slowing
factor, MSF) capable of reducing the electro-
phoretic mobility of guinea-pig macrophages.
The slowing of macrophages was shown to be
related to the host malignant condition and
a nonspecific test, the macrophage electro-
phoretic mobility (MEM) test for cancer was
proposed. This was confirmed by Pritchard
et al. (Lancet, 1972, ii, 627). The MEM test
in its original form was technically difficult
to operate for two main reasons: (a) the
equipment available to measure the electro-
phoretic mobility of macrophages was prone
to many technical faults and (b) the selection
of slowed macrophages within the macro-
phage population required considerable
training. In order that the MEM test could
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terms, certain lines of development were
undertaken: (1) Development of an electro-
phoresis apparatus which was stable and easy
to operate; (2) to increase the percentage
slowing of the macrophages so that recog-
nition of such cells would be prone to less
error; (3) characterization of the component
produced and released by the sensitized
lymphocytes-the macrophage slowing factor
MSF; (4) evaluation of the test in non-
malignant disease situations.
A new electrophoresis apparatus has been
designed and built. This apparatus has
formed the basis of many modifications and
is now in the process of evaluation with
close-circuit television. The new apparatus
allows for a greater number of samples to be
measured, associated with minimum operator
fatigue.
The percentage slowing of macrophages,
and hence the percentage positivity obtained
in the MEM test, can be increased by in-
creasing the number of lymphocytes in the
test system and increasing the radiation dose
to the macrophages. Percentage macrophage
slowing can also be increased by adopting a
split incubation regimen viz. (1) Lymphocytes
and antigen 23°C 90 min-supernatant from
(1) to guinea-pig macrophages-37°C 90 min.
This modification has resulted in the per-
centage slowing from malignant conditions
being increased from the standard range
15-20% to 23-40% without any correspond-
ing effect on the " normals ". This MOD-
MEM test has now been adopted as standard.
Electron micrograph studies of lympho-
cyte cell surfaces and macrophage cell
surfaces have failed to reveal any visible
changes. Column chromatography (Sepha-
dex) has shown that the slowing factor may
be split into two active components of
differing molecular weight; one component of
M.W. 20,000 and another of M.W. 8000, the
latter being capable of producing more
macrophage slowing than the former. Slow-
ing factor is heat stable. Attempts to detect
slowing factor on S.D.S. polyacrylamide gel
electrophoresis were unsuccessful because of
concentration effects and lack of reproduci-
bility. Histone fractions F2A1 and F2A2
have been shown to have a sequence analogy
with the basic encephalogenilitic factor used
as the " antigen " in the MOD-MEM test.
These fractions can replace the EF as
antigen but concentrations have to be
carefully monitored as such histone prepara-
tions are nonspecific in causing macrophage
slowing.
The results of a small pilot study of the
operation of the MEM test in non-malignant
disease indicated that the specificity of the
test for cancer was notnecessarily maintained.
In general, specific inflammatory and meta-
bolic disease did not produce results within
the cancer range. Degenerative diseases
involving nerve tissue produced positive
results within the cancer range. Pregnanev
did not give positive results. Of 115 cases
studied, 13 gave positive results in the MOD-
MEM test, where sensitization could not be
attributed to a specific cause. This group
consisted of subjects suffering from chronic
bronchitis, rheumatic fever and duodenal
ulcers. Thesecases arebeingfollowed. One case
of adenocarcinoma and disseminated sclerosis
gave negative MOD-MEM results.
CLINICAL EXPERIENCE WITH THE
MAKARI TUMOUR SKIN TEST. D.E.H.
TEE. Department of Immunology, King's
College Hospital Medical School.
The double-blind evaluation ofthe Makari
intradermal test was started nearly 5 years
ago and is still continuing. The test is based
upon the measurement of the local erythe-
matous reactions of the skin to a series of
intradermal injections of cancer derived
antigens which have been pre-incubated with
the patient's serum. These antigens have
been prepared from human tumour material
by the application of major physical and
chemical degradative procedures. The
patients examined were those referred to
King's College Hospital, the majority ofwhom
had signs and symptoms which suggested the
presence of malignant disease.
Our previously published studies, the last
of which consisted of 584 patients, have
confirmed that positive intradermal tests are
seen in many, but not all, patients with
malignant tumours arising in different organs,
including those of the digestive, respiratory
and genito-urinary systems. In subjects with
carcinoma the response to the test was
related to the stage of the carcinomatous
process, the largest proportion of positive
tests occurring in patients with early disease.
An appreciable proportion of positive test
results were also observed in diseases asso-
ciated with inflammatory and reactive pro-
cesses. Thus, our published studies suggested